eli lilly retatrutide trial just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Lilly's triple agonist, retatrutide, delivered

In the phase 1b combination trial, 37% of all reported adverse events were gastrointestinal disorders [3]

It is legal and common for clinicians to prescribe drugs off-label: however, this puts pharmacists in a difficult position if they have to say a patient has diabetes when they do not for the savings card

Mike represents individuals who are seriously

In a study by Cengiz et al., a mathematical model suggested that this strategy could be more effective than the weekly dose Im no proponent of microdosing but we are gathering anecdotal evidence at a rapid pace and need to study it to determine if it has merit in post loss maintenance

What oral GLP-1 actually means in 2026 Until recently, every GLP-1 receptor agonist used for weight loss was an injection

NA: not available